- Home
- MGM vs BBIO Comparison
MGM vs BBIO Comparison
Compare MGM & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGM
- BBIO
- Stock Information
- Founded
- MGM 1986
- BBIO 2015
- Country
- MGM United States
- BBIO United States
- Employees
- MGM N/A
- BBIO N/A
- Industry
- MGM Hotels/Resorts
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- MGM Consumer Discretionary
- BBIO Health Care
- Exchange
- MGM Nasdaq
- BBIO Nasdaq
- Market Cap
- MGM 9.8B
- BBIO 9.4B
- IPO Year
- MGM N/A
- BBIO 2019
- Fundamental
- Price
- MGM $32.32
- BBIO $55.32
- Analyst Decision
- MGM Buy
- BBIO Strong Buy
- Analyst Count
- MGM 15
- BBIO 16
- Target Price
- MGM $47.62
- BBIO $64.44
- AVG Volume (30 Days)
- MGM 5.1M
- BBIO 2.0M
- Earning Date
- MGM 10-29-2025
- BBIO 11-11-2025
- Dividend Yield
- MGM N/A
- BBIO N/A
- EPS Growth
- MGM N/A
- BBIO N/A
- EPS
- MGM 1.84
- BBIO N/A
- Revenue
- MGM $17,211,652,000.00
- BBIO $235,812,000.00
- Revenue This Year
- MGM $1.64
- BBIO $115.46
- Revenue Next Year
- MGM $2.02
- BBIO $65.03
- P/E Ratio
- MGM $17.55
- BBIO N/A
- Revenue Growth
- MGM 0.76
- BBIO 7.62
- 52 Week Low
- MGM $25.30
- BBIO $21.72
- 52 Week High
- MGM $42.54
- BBIO $55.30
- Technical
- Relative Strength Index (RSI)
- MGM 32.14
- BBIO 59.91
- Support Level
- MGM $33.59
- BBIO $52.97
- Resistance Level
- MGM $35.55
- BBIO $55.13
- Average True Range (ATR)
- MGM 1.04
- BBIO 1.58
- MACD
- MGM -0.25
- BBIO 0.16
- Stochastic Oscillator
- MGM 1.49
- BBIO 84.41
About MGM MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 37,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Park MGM, Luxor, New York-New York, and Bellagio. The Strip contributed approximately 59% of total EBITDAR in 2024. MGM also owns US regional assets, which represented a low 20s share of 2024 EBITDAR (MGM's Macao EBITDAR was 21% of the total in 2024). MGM's US sports and i-gaming operations are currently a high-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM China casinos with a new property that opened on the Cotai Strip in early 2018. We estimate MGM will open a resort in Japan in 2030.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.